From c51a401521270637bec6655c754c01a40d8bc0ae Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 17:59:57 +0000 Subject: [PATCH 1/2] extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...t cost impact inflationary through 2035.md | 6 +++++ ...ients-undermining-chronic-use-economics.md | 6 +++++ ...dification-efficacy-combined-approach.json | 25 +++++++++++++++++++ ...modification-efficacy-combined-approach.md | 15 ++++++++++- 4 files changed, 51 insertions(+), 1 deletion(-) create mode 100644 inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index bf3d0570..35329762 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -89,6 +89,12 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment. + +### Additional Evidence (challenge) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18* + +If GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), then the chronic use assumption may be wrong. Patients who establish exercise habits during a 1-2 year medication window may not need indefinite treatment, fundamentally changing the cost trajectory. The inflationary projection assumes continuous medication; the combination data suggests a time-limited intervention model may be viable. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 40852332..f2cf0e53 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -77,6 +77,12 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on. + +### Additional Evidence (extend) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18* + +Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain (vs 7.6 kg placebo) while GLP-1 + exercise produces only 3.5 kg regain. This means low persistence may be economically rational for patients if the medication alone doesn't create lasting value—the 15% two-year persistence rate may reflect patients discovering that medication without lifestyle change produces temporary results. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json b/inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json new file mode 100644 index 00000000..20ebfd0d --- /dev/null +++ b/inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json @@ -0,0 +1,25 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 2, + "rejected": 1, + "fixes_applied": [ + "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:set_created:2026-03-18", + "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d" + ], + "rejections": [ + "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-18" +} \ No newline at end of file diff --git a/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md b/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md index 3c5435d2..bc2eaa49 100644 --- a/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md +++ b/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md @@ -7,9 +7,13 @@ date: 2026-03-01 domain: health secondary_domains: [] format: review -status: unprocessed +status: enrichment priority: high tags: [glp-1, lifestyle-modification, exercise, sarcopenia, muscle-preservation, adherence, weight-regain, obesity] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -75,3 +79,12 @@ Synthesis of 2025-2026 research on combining lifestyle modifications (diet, exer PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate) WHY ARCHIVED: The "exercise is the active ingredient for weight maintenance" finding significantly changes how to evaluate BALANCE model design and GLP-1 economic models under VBC EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison — this is the claim-worthy finding. Also note the BALANCE model design needs evaluation against this evidence. + + +## Key Facts +- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits' +- Meta-analysis of 22 RCTs with 2,258 participants found ~25% of GLP-1 weight loss is lean mass +- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced +- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions +- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) +- BALANCE model includes lifestyle support component but specific exercise programming details not specified in source -- 2.45.2 From 4f2540e59970dcb262e9c7be3989a3e6f324f81c Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 18:00:45 +0000 Subject: [PATCH 2/2] auto-fix: strip 2 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...model makes the net cost impact inflationary through 2035.md | 2 +- ...abetic-obesity-patients-undermining-chronic-use-economics.md | 2 +- 2 files changed, 2 insertions(+), 2 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 35329762..c50de4dd 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -85,7 +85,7 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu ### Additional Evidence (challenge) -*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-18* +*Source: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination | Added: 2026-03-18* WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index f2cf0e53..c6673443 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -73,7 +73,7 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre ### Additional Evidence (extend) -*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-18* +*Source: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination | Added: 2026-03-18* WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on. -- 2.45.2